Pharmacokinetics, Efficacy, and Safety of Darunavir/Ritonavir 800/100 mg Once-Daily in Treatment-Naïve and -Experienced Patients

REFERENCES

• Clumeck N, Pozniak A, Raffi F, the EACS Executive Com-mittee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med. 2008;9:65–71.
   PubMed Web of Science ®Google Scholar
• Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir OF, em-tricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251–260.
   PubMed Web of Science ®Google Scholar
• Moyle GJ, DeJesus E, Cahn P, et al. Abacavir once or twice-daily combined with once-daily lamivudine and efa-virenz for the treatment of antiretroviral-naive HIV-infected adults: Results of the Ziagen Once-daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr 2005; 38:417–425.
   PubMed Web of Science ®Google Scholar
• van Leth F, Phanuphak P, Ruxrungtham K, et al. Compari-son of first-line antiretroviral therapy with regimens includ-ing nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study. Lancet. 2004;363:1253–1263.
   PubMed Web of Science ®Google Scholar
• Boffito M, Collot-Teixeira S, De Lorenzo F, et al. Plasma ex-posure of 100 mg once and twice-daily decreases HDL and CD36 expression but only twice-daily dosing increases triglycerides: Potential effect of ritonavir on cardiovascular disease. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; February 3–6, 2008; Boston, MA. Abstract 930.
   Google Scholar
• von Wyl V, Yerly S, Boni J, et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating com-bination antiretroviral treatment: A comparison of different regimen types. Arch Intern Med. 2007;167:1782–1790.
   PubMed Web of Science ®Google Scholar
• Gupta R, Hill A, Pillay D. Drug resistance after virological failure of first-line HAART in resource rich and poor set-tings-a meta-analysis. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infec-tions; February 3–6, 2008; Boston, MA. Abstract 891.
   Google Scholar
• Molina J, Andrade-Villanueva J, Echevarria J, et al. Efficacy and safety of once-daily atazanavir-ritonavir compared to twice-daily lopinavir-ritonavir, each in combination with tenofovir and emtricitabine in ARV-naïve HIV-1 infected subjects: The CASTLE study, 48 week results. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; February 3–6, 2008; Boston, MA. Abstract 37.
   Google Scholar
• Smith K, Fine D, Patel P, et al. Efficacy and safety of aba-cavir/lamivudine compared to tenofovir/emtricitabine in combination with once-daily lopinavir-ritonavir through 48 weeks in the HEAT study. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infec-tions; February 3–6, 2008; Boston, MA. Abstract 774.
   Google Scholar
• Gathe J, daSilva B, Loufty M, et al. Study M05-730 primary efficacy results at week 48: Phase 3, randomized, open-label study of lopinavir-ritonavir (LPV/r) tablets once-daily (OD) versus twice-daily (BID), co-administered with tenofo-vir (TDF) + emtricitabine (FTC) in antiretroviral naive (ARV) HIV-1 infected subjects. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infec-tions; February 3–6, 2008; Boston, MA. Abstract 775.
   Google Scholar
• DeJesus E, Ortiz R, Khanlou H, et al. Efficacy and safety of darunavir/ritonavir versus lopinavir/ritonavir in ARV treatment-naive HIV-1-infected patients at Week 48: AR-TEMIS (TMC114-C211). In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–20, 2007; Chicago, IL. Ab-stract H–718b.
   Google Scholar
• Ananworanich J, Hill A, Siangphoe U, et al. A prospective study of efficacy and safety of once-daily saquinavir/rito-navir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients. Antivir Ther 2005;10:761–767.
   PubMed Web of Science ®Google Scholar
• Hicks C, DeJesus E, Sloan L, et al. Efficacy and safety of once-daily fosamprenavir-ritonavir (FPV/r) with abacavir-lamivudine fixed dose combination in antiretroviral naive HIV infected patients: 24-week results from COL100758. In: Program and abstracts of the 8th International Con-gress on Drug Therapy in HIV Infection; November 12–16, 2006; Glasgow, UK. Abstract P2.
   Google Scholar
• Smith K, Weinberg W, DeJesus E, et al. Once-daily fosam-prenavir or atazanavir, both boosted by ritonavir 100mg, plus tenofovir/emtricitabine combination tablet: A planned week 24 interim analysis of the ALERT study. In: Program and abstracts of the 8th International Congress on Drug Therapy in HIV Infection; November 12–16, 2006; Glasgow, UK. Abstract P1.
   Google Scholar
• Boffito M, Else L, Back D, Taylor J, Khoo S, Sousa M, Phar-macokinetics (PK) of atazanavir/ritonavir (ATV/r) once-daily (OD) and lopinavir/ritonavir (LPV/r) twice-daily (BD) and OD over 72 hours following drug intake cessation. In: Program and abstracts of the 11th European AIDS Conference; Oc-tober 24–27, 2007; Madrid, Spain. Abstract LBPS 7.5.
   Google Scholar
• DeJesus E, LaMarca A, Sension M, Beltran C, Yeni P. The Context Study: Efficacy and safety of GW433908/RTV in protease inhibitor-experienced subjects with virological failure (24 week results). In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infec-tions; February 10–14, 2003; Boston, MA. Abstract 178.
   Google Scholar
• Naeger LK, Struble KA. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients. AIDS. 2006;20:847–853.
   PubMed Web of Science ®Google Scholar
• De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005;49:2314–2321.
   PubMed Web of Science ®Google Scholar
• Hoetelmans R, Van der Sandt I, De Pauw M, et al. TMC114, a next generation HIV protease inhibitor: Pharmacokinetics and safety following oral administration of multiple doses with and without low doses of ritonavir in healthy volun-teers. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10–14, 2003; Boston, MA. Abstract and poster 549.
   Google Scholar
• Cvetkovic RS, Goa KL. Lopinavir/ritonavir: A review of its use in the management of HIV infection. Drugs. 2003;63: 769–802.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb. Atazanavir (atazanavir capsules) US prescribing information. Available at http://packageinserts.bms.com/pi/pi_reyataz.pdf. Accessed February 2008.
   Google Scholar
• Sekar V, Vanden Abeele C, Van Baelen B, Vis P, Lavreys L, De Pauw M. Pharmacokinetic-pharmacodynamic analyses of once-daily darunavir-ritonavir in the ARTEMIS study. In: Program and abstracts of the 15th Conference on Retro-viruses and Opportunistic Infections; February 3–6, 2008; Boston, MA. Abstract 769.
   Google Scholar
• Arastéh K, Clumeck N, Pozniak A, et al. TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: A 14-day proof-of-principle trial. AIDS. 2005;19:943–947.
   PubMed Web of Science ®Google Scholar
• Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 2007;21:395–402.
   PubMed Web of Science ®Google Scholar
• Haubrich R, Berger D, Chiliade P, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS. 2007;21:F11—F18.
   PubMed Web of Science ®Google Scholar
• Boffito M, Moyle G, Hill A, et al. The pharmacokinetic profile of darunavir with low-dose ritonavir (DRV/r) in various multiple-dose regimens over 120 hours. 9th International Workshop on Clinical Pharmacology of HIV Therapy; April 7–9, 2008; New Orleans, USA. Abstract P31.
   Google Scholar
• Arasteh K, Clumeck N, Pozniak A, et al. First clinical results on antiretroviral activity, pharmacokinetics, and safety of TMC114, an HIV-1 protease inhibitor, in multiple PI expe-rienced patients. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10–14, 2003; Boston, MA. Abstract 8.
   Google Scholar
• De Meyer S, Spinoza-Guzman S, Vangenuegden T, de Bet-hune M, Miralles D. Efficacy of darunavir (DRV)/r 800/100 mg qd in patients with low DRV resistance. In: Program and abstracts of the 5th European HIV Drug Resistance Work-shop; March 28–30, 2007; Cascais, Portugal. Abstract 48.
   Google Scholar
• Madruga J, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: A randomized, controlled Phase III trial. Lancet. 2007; 370:49–58.
   PubMed Web of Science ®Google Scholar
• Cooper D, Gatell J, Rockstroh J, et al. Results of BENCHMRK-1, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: Program and abstracts of the 14th Conference on Retroviruses and Op-portunistic Infections; February 25–28, 2007; Los Angeles, CA. Abstract 105aLB.
   Google Scholar
• Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a ran-domised, double-blind, placebo-controlled trial. Lancet. 2007;370:29–38.
   PubMed Web of Science ®Google Scholar